Lung Volume Change Assessment in Moderate and Severe COVID-19 Using CT Volumetry.

Publication date: Jun 09, 2025

Background/Objectives: Background: COVID-19 pneumonia leads to alveolar collapse and parenchymal infiltration, contributing to lung volume loss and respiratory failure. Objectives: To quantify lung volume loss and recovery in moderate and severe cases, explore mechanisms of respiratory failure, and correlate imaging findings with histopathological changes. Methods: We retrospectively analyzed 43 patients with moderate/severe COVID-19. CT scans from the acute phase and at 3-12 months follow-ups were processed using 3D Slicer. Infiltrated (-650 to -200 HU) and collapsed (-200 to 0 HU) lung regions were quantified and summed to define the affected lung volume. CT severity scores and total affected percentage were compared with lung volume loss. Histopathological analysis of three autopsy cases was used to support imaging findings. Results: Median acute phase lung volume loss was 30. 6%. Patients with 50% affected lung had median losses of 6. 5%, 35. 7%, and 39. 8%, respectively. Volume loss strongly correlated with affected lung percentage (r = 0. 72, p < 0. 000001) and moderately with CT severity score (r = 0. 52, p < 0. 01). Histology confirmed alveolar area reductions over 65% in infiltrated regions. Conclusions: Lung volume loss reflects both imaging severity and histopathological damage, offering insights into the mechanisms of COVID-19 respiratory failure. CT volumetry is a valuable tool for assessing parenchymal injury and monitoring recovery, and 3D Slicer provides an accessible platform for implementing this approach.

Open Access PDF

Concepts Keywords
Basel 3D Slicer
Histology affected lung
Pneumonia alveolar collapse
Respiratory COVID-19
CT volumetry
respiratory failure

Semantics

Type Source Name
disease MESH COVID-19
disease MESH pneumonia
disease MESH respiratory failure
disease MESH Infectious Diseases
disease MESH Emergency
disease MESH Lung injuries
disease IDO replication
disease IDO process
drug DRUGBANK Angiotensin II
disease MESH inflammation
disease MESH edema
disease IDO production
disease MESH fibrosis
disease MESH lung diseases
drug DRUGBANK Diethyltoluamide
drug DRUGBANK Isoxaflutole
disease MESH surfactant dysfunction
disease MESH hypercoagulability
disease MESH oxygen deficiency
disease MESH sepsis
disease MESH pulmonary fibrosis
disease MESH pulmonary hypertension
drug DRUGBANK Trihexyphenidyl
disease MESH viral pneumonia
disease MESH abnormalities
drug DRUGBANK Formaldehyde
drug DRUGBANK Coenzyme M
disease MESH critically ill
drug DRUGBANK Bentiromide
disease MESH acute respiratory distress syndrome
disease MESH influenza
disease MESH respiratory infections
drug DRUGBANK Trestolone
disease MESH infection
disease MESH cytokine storm
drug DRUGBANK Guanosine
disease MESH Pulmonary Edema
disease MESH necrosis
disease MESH clinical relevance
drug DRUGBANK Nonoxynol-9
drug DRUGBANK Isosorbide Mononitrate
disease MESH Polysplenia Syndrome
drug DRUGBANK Carboxyamidotriazole
drug DRUGBANK Troleandomycin

Original Article

(Visited 6 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *